Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

X-ray Crystallography-Guided Design and Synthesis of Cyclopentyl Heteroaryl Carboxylic Acid-Based Inhibitors of the SARS-CoV-2 Nsp3 Macrodomain (Mac1).

Journal of medicinal chemistry·2026

Same author

Inhibition of MLLT1 Limits Growth of KMT2A::AFF1 Leukemias Without Killing Healthy Hematopoietic Stem Cells.

Experimental hematology·2026

Same author

Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.

Molecular cancer therapeutics·2026

Same author

Deciphering cytokine-driven ADP-ribosylation signaling networks via Af1521-based mass spectrometry analysis of labile Glu/Asp-linkages.

Nature communications·2026

Same author

Fragment-Based Design of Targeted Covalent Inhibitors: The Scope and Limitation of Linking Approaches.

ChemMedChem·2026

Same author

Simple tone curves: theory and applications.

The Visual computer·2026

Search research articles

Related Experiment Video

Updated: Aug 8, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors.

Marion Schuller¹, Tryfon Zarganes-Tzitzikas², James Bennett²

¹Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Pathogens (Basel, Switzerland)

|February 25, 2023

Summary

Researchers identified small molecules and FDA-approved drugs that inhibit the NSP3 macrodomain, a key target for developing new antiviral therapies against coronaviruses like SARS-CoV-2.

Keywords:

ADP-ribosylation COVID-19 SARS-CoV-2 drug discovery and development macrodomain non-structural protein 3 (NSP3)virtual screening

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Related Experiment Videos

Last Updated: Aug 8, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Area of Science:

Virology and Drug Discovery
Molecular Biology and Biochemistry

Background:

The COVID-19 pandemic underscores the need for rapid antiviral strategies.
The NSP3 macrodomain of coronaviruses, including SARS-CoV-2, is crucial for viral replication and pathogenicity, making it a promising therapeutic target.

Purpose of the Study:

To identify and characterize inhibitors of the SARS-CoV-2 NSP3 macrodomain.
To explore novel antiviral drug development avenues by understanding structure-activity relationships.

Main Methods:

Combined virtual screening and biophysical screening to identify potential inhibitors.
Performed analogue characterization and crystallographic studies to confirm binding modes.

Main Results:

Discovered several experimental small molecules and FDA-approved drugs that inhibit the NSP3 macrodomain.
Confirmed binding of inhibitors, including aztreonam, to the NSP3 macrodomain active site through crystallography.
Gained valuable structure-activity relationship insights for NSP3 macrodomain inhibitor development.

Conclusions:

NSP3 macrodomain inhibitors represent a viable strategy for developing novel antiviral therapies.
Structure-activity relationship data from this study will guide future development of potent and specific NSP3 inhibitors.
This research provides a foundation for enhancing preparedness against future viral disease outbreaks.